ScreenerHero
MXCTMaxCyte Inc. Common Stock
NAS · US · Healthcare · Medical Devices · maxcyte.com
1.380USD-0.72%Mkt Cap: 142.42M $P/E: —

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrume…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$203.17BUSDP/E 37.7
SYK
Stryker Corporation
$126.37BUSDP/E 34.2
MDT
Medtronic plc
$119.49BUSDP/E 25.0
BSX
Boston Scientific Corporation
$73.00BUSDP/E 20.4
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
EW
Edwards Lifesciences Corporation
$51.70BUSDP/E 53.4
DXCM
DexCom, Inc.
$34.85BUSDP/E 36.5
GEHC
GE HealthCare Technologies Inc. Common Stock
$34.04BUSDP/E 17.2
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
PHG
Koninklijke Philips N.V.
$26.80BUSDP/E 20.8
STE
STERIS plc
$23.20BUSDP/E 29.1
ZBH
Zimmer Biomet Holdings, Inc.
$19.26BUSDP/E 24.5
PEN
Penumbra, Inc.
$12.81BUSDP/E 79.7
SNN
Smith & Nephew plc
$12.25BUSDP/E 19.9
SN
Smith & Nephew plc
$11.48BUSDP/E 19.8
GMED
Globus Medical, Inc.
$11.67BUSDP/E 22.2
GKOS
Glaukos Corp
$10.91BUSD
EUZ
Eckert & Ziegler Strahlen-und Medizinte AG
$10.01BUSDP/E 17.1
PODD
Insulet Corporation
$10.28BUSDP/E 27.5
BIO
Bio-Rad Laboratories, Inc. Class A
$10.17BUSDP/E 46.3
HeadlineSourceTime
Older
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

Revenue declined 15% year-over-year, but net losses narrowed significantly.

Motley Fool
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...

MaxCyte Inc (MXCT) navigates a transitional quarter with a landmark Genentech deal and robust CASGEVY royalties, positioning for renewed growth in the second half of 2026.

GuruFocus.com
MaxCyte, Inc. Q2 2026 Earnings Call Summary

Moby summary of MaxCyte, Inc.'s Q2 2026 earnings call

Moby
MaxCyte Q2 Earnings Call Highlights

MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectation

MarketBeat
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates

Adherex Technologies (FENC) delivered earnings and revenue surprises of +400.00% and +11.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks